ATE210439T1 - Verfahren und mittel zur inhibierung von proteinkinasen - Google Patents

Verfahren und mittel zur inhibierung von proteinkinasen

Info

Publication number
ATE210439T1
ATE210439T1 AT95941340T AT95941340T ATE210439T1 AT E210439 T1 ATE210439 T1 AT E210439T1 AT 95941340 T AT95941340 T AT 95941340T AT 95941340 T AT95941340 T AT 95941340T AT E210439 T1 ATE210439 T1 AT E210439T1
Authority
AT
Austria
Prior art keywords
independently represents
protein kinases
inhibiting protein
double bond
together represent
Prior art date
Application number
AT95941340T
Other languages
English (en)
Inventor
Neill A Giese
Nathalie Lokker
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Application granted granted Critical
Publication of ATE210439T1 publication Critical patent/ATE210439T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
AT95941340T 1994-10-28 1995-10-26 Verfahren und mittel zur inhibierung von proteinkinasen ATE210439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/332,597 US5795910A (en) 1994-10-28 1994-10-28 Method and compositions for inhibiting protein kinases
PCT/US1995/013882 WO1996013259A2 (en) 1994-10-28 1995-10-26 Method and compositions for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
ATE210439T1 true ATE210439T1 (de) 2001-12-15

Family

ID=23298937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941340T ATE210439T1 (de) 1994-10-28 1995-10-26 Verfahren und mittel zur inhibierung von proteinkinasen

Country Status (14)

Country Link
US (3) US5795910A (de)
EP (1) EP0788356B9 (de)
JP (1) JPH10508024A (de)
KR (1) KR970706812A (de)
CN (1) CN1165481A (de)
AT (1) ATE210439T1 (de)
AU (1) AU706621B2 (de)
CA (1) CA2203757A1 (de)
DE (1) DE69524628T2 (de)
DK (1) DK0788356T3 (de)
ES (1) ES2170172T3 (de)
PT (1) PT788356E (de)
TW (1) TW467743B (de)
WO (1) WO1996013259A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
JP4014639B2 (ja) * 1996-08-06 2007-11-28 セイコーエプソン株式会社 液晶表示装置及びそれを用いた電子機器
US6087352A (en) * 1998-08-17 2000-07-11 Trout; William E. Use of Zeranol to modulate reproductive cycles
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
US20020182268A1 (en) * 1998-12-07 2002-12-05 Bessette Steven M. Cancer treatment compositions and method using natural plant essential oils
WO2000038674A1 (en) 1998-12-24 2000-07-06 Novation Pharmaceuticals Inc. COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
CN1208087C (zh) * 1999-08-13 2005-06-29 斯克里普斯研究学院 可用于采用蛋白激酶Raf和Ras调节血管生成的方法和组合物
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
US6565864B2 (en) 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
WO2002064809A2 (en) * 2001-02-09 2002-08-22 Unilever N.V. Process for the preparation of one or more statins by fermentation
EP1450784A4 (de) * 2001-11-09 2005-02-09 Conforma Therapeutics Corp Hsp90-hemmende zearalanol-verbindungen und verfahren zu ihrer herstellung und verwendung
FR2835252B1 (fr) * 2002-01-25 2005-08-05 Seppic Sa Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau
CN1653059A (zh) * 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物
US7915306B2 (en) * 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
CA2482940A1 (en) * 2002-04-17 2003-10-23 Taisho Pharmaceuticals Co., Ltd. Hair growth tonic
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1608338A1 (de) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmazeutische zusammensetzungen enthaltend wirkstoffe mit einer lactongruppe und übergangsmetallionen
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
JP2008514635A (ja) * 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
EP1962803A1 (de) * 2005-12-23 2008-09-03 Alcon, Inc. Pharmazeutische formulierung zur verabreichung rezeptor-tyrosin-kinase-hemmender verbindungen ins auge
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
JP5465006B2 (ja) 2006-08-11 2014-04-09 ユニベルシテ・ドウ・ストラスブール キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
KR101667960B1 (ko) * 2007-07-25 2016-10-20 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
EP2453234B1 (de) 2007-10-29 2014-01-15 Eisai R&D Management Co., Ltd. Verfahren zur Vorhersage der Fähigkeit einer Zearalenon-Analogverbindung zur Behandlung von Krebs
RU2478630C2 (ru) 2007-12-07 2013-04-10 ЭЙСАН Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД. Промежуточные соединения и способы получения зеараленоновых макролидных аналогов
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN101928700B (zh) * 2009-07-28 2012-05-02 北京恒宇视野生物科技有限公司 蛋白激酶pftk1单克隆抗体及其制备方法
WO2012021974A1 (en) * 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2016196256A2 (en) 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
JPS6239558A (ja) * 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−シアノアクリル酸アミド誘導体
JPS6239523A (ja) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242923A (ja) * 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242925A (ja) * 1985-08-20 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4842862A (en) * 1986-07-03 1989-06-27 International Minerals & Chemical Corp. Immunostimulating agents
GB9225396D0 (en) * 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
US5728726A (en) 1998-03-17
EP0788356B9 (de) 2002-10-02
MX9703113A (es) 1998-06-30
WO1996013259A2 (en) 1996-05-09
EP0788356B1 (de) 2001-12-12
JPH10508024A (ja) 1998-08-04
DE69524628T2 (de) 2002-08-08
DK0788356T3 (da) 2002-03-18
PT788356E (pt) 2002-06-28
US5795910A (en) 1998-08-18
TW467743B (en) 2001-12-11
WO1996013259A3 (en) 1996-08-01
CN1165481A (zh) 1997-11-19
AU4278996A (en) 1996-05-23
AU706621B2 (en) 1999-06-17
US5674892A (en) 1997-10-07
EP0788356A2 (de) 1997-08-13
CA2203757A1 (en) 1996-05-09
DE69524628D1 (de) 2002-01-24
KR970706812A (ko) 1997-12-01
ES2170172T3 (es) 2002-08-01

Similar Documents

Publication Publication Date Title
DE69524628D1 (de) Verfahren und mittel zur inhibierung von proteinkinasen
TR199902406T2 (xx) Kristalli cefdinir amin tuz.
GEP20063830B (en) Nogo Receptor-Mediated Blockade of Axonal Growth
DE69524365D1 (de) Verfahren zur Isolierung und Reinigung von 2'-Deoxy-2',2'-difluornucleosiden
TR199701056T1 (xx) Farnesil-protein transferaz enzimi inhibit�rleri.
DE69603240D1 (de) Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
DE69602638D1 (de) Naphthylverbindungen, Zwischenprodukte, Zusammensetzungen und Methoden
DE69434955D1 (de) Aryliden und Heteroaryliden-oxindolderivate als Tyrosin Kinase Inhibitoren
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
ATE231505T1 (de) Neue heterocyclische/cyclische amine
DE69611028D1 (de) Verfahren zur Isomerisierung von Olefinen
DE69739026D1 (de) Nitril-Hydratase, ihre Derivate und Verfahren zur Herstellung von Verbindungen
PT1083903E (pt) Indenopirrolocarbazoles em ponte
DE3854003D1 (de) Verfahren zur Herstellung von N-substituiertem Amin.
EP0656791A4 (de) Therapeutische zusammensetzungen und verfahren unter verwendung von pqq.
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
ATE176668T1 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
DE69330977D1 (de) Verfahren zur Herstellung von Hydroxylfunktionen enthaltenden Derivaten von epoxidierten Dien-Blockcopolymeren
DE69737609D1 (de) Prenyl transferase inhibitoren
EP0577699A4 (de) Zusammensetzungen und verfahren zur hemmung der aktivierung des aktiven faktors xiii.
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
EP0787123A4 (de) Farnesyl-protein transferase inhibitoren
DE69536133D1 (de) Methode zur Reinigung von Keratinozyten-Wachstumfaktoren
DE69314644D1 (de) Verfahren zur isomerisierung von 1,1,2-trichlortrifluorethan
DE69812395D1 (de) Verfahren zur synthese von taxanen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee